<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-28721" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Sarcoidosis</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Bokhari</surname>
            <given-names>Syed Rizwan A.</given-names>
          </name>
          <aff>Tulane Un, Un Med Center New Orleans</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Zulfiqar</surname>
            <given-names>Hassam</given-names>
          </name>
          <aff>Hamad Medical Corporation, Doha, Qatar</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Mansur</surname>
            <given-names>Abeera</given-names>
          </name>
          <aff>Kearney Regional Medical Center, Kearney, Nebraska</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Syed Rizwan Bokhari declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Hassam Zulfiqar declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Abeera Mansur declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>25</day>
          <month>6</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-28721.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Sarcoidosis is a multisystem disorder of unknown etiology characterized by noncaseating granulomas in organs. This condition mostly affects young adults and characteristically presents with reticular opacities in the lungs and bilateral hilar lymphadenopathy. Other involved sites include eyes, skin, joints, and in some cases, the reticuloendothelial system, musculoskeletal system, exocrine glands, heart, kidney, and central nervous system. This activity outlines the evaluation and management of sarcoidosis and explains the role of the interprofessional team in improving care for patients with this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the characteristic signs and symptoms of sarcoidosis.</p></list-item><list-item><p>Explain how to diagnose sarcoidosis.</p></list-item><list-item><p>Describe the appropriate monitoring for asymptomatic, non-progressive sarcoidosis.</p></list-item><list-item><p>Summarize the importance of collaboration and communication among the interprofessional team to monitor symptoms and progression of the asymptomatic disease, which will improve outcomes for patients with sarcoidosis.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=28721&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=28721">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-28721.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Sarcoidosis is a multisystem disorder of unknown etiology that mostly affects young adults worldwide and presents with noncaseating granulomas in various organs. Characteristically, it presents with bilateral hilar lymphadenopathy and reticular opacities in the lungs. Other major involved sites include skin, eyes, and joints. However, it can be expressed to a variable degree in the musculoskeletal system, reticuloendothelial system, exocrine glands, heart, kidney, and central nervous system.<xref ref-type="bibr" rid="article-28721.r1">[1]</xref><xref ref-type="bibr" rid="article-28721.r2">[2]</xref><xref ref-type="bibr" rid="article-28721.r3">[3]</xref></p>
      </sec>
      <sec id="article-28721.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>It is an inflammatory disease of unknown etiology that manifests as noncaseating granulomas in multiple systems. Various&#x000a0;associations have been described, including&#x000a0;occupational and environmental exposures to beryllium, dust, and other agents causing asthma. Various&#x000a0;microorganisms like mycobacteria and propionibacteria have been associated.&#x000a0;Possible infective etiology has been described in a few studies where sarcoidosis developed in a previously negative individual after cardiac or bone marrow transplantation.<xref ref-type="bibr" rid="article-28721.r4">[4]</xref><xref ref-type="bibr" rid="article-28721.r5">[5]</xref></p>
        <p>Genetic components and disease in more than one family member are usually related to antigens of the major histocompatibility complex (MHC), especially DR alleles. Few studies have described other less common genomes and angiotensin-converting enzyme genotypes in a few patients.</p>
        <p>Cytokines, including Th1, IL-2, IL6, IL 8, IL12, IL 18, IL 27, and interferon (IFN) gamma and tumor necrosis factor (TNF) alpha are closely associated with sarcoidosis. Few of these are implicated in granuloma formation with macrophage and epithelioid accumulation, activation, and aggregation. Some of these interleukins are believed to act as disease modifiers.</p>
      </sec>
      <sec id="article-28721.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>The incidence is 11 cases per 100,000 in whites but 34 cases per 100,000 in African Americans, with a lifetime risk of 2.4 percent in the United States. Extrapulmonary sarcoid is seen in up to 25 to 30 percent of patients. Cardiac involvement is seen more commonly in males, while skin and eye features are more prominent in women. Extrapulmonary features can differ in age of presentation, gender, and ethnicity.<xref ref-type="bibr" rid="article-28721.r6">[6]</xref><xref ref-type="bibr" rid="article-28721.r7">[7]</xref></p>
      </sec>
      <sec id="article-28721.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Pathogenesis of cutaneous sarcoidosis is poorly understood and attributable to both genetic and environmental factors. A key role in the development of sarcoidosis is played by T cells as they promote cellular immune reaction and are usually associated with an inverted CD4/CD8 ratio. It is well characterized by noncaseating granuloma, typically containing macrophages, multinucleated giant cells, and epithelioid cells, in addition to lymphocytes, monocytes, mast cells, and fibroblasts. There is a role of&#x000a0;tumor necrosis factor (TNF) and TNF receptors, as both are increased in this disease. This has been evidenced by the role of anti-TNF agents, such as pentoxifylline and&#x000a0;infliximab. In addition to the T cell's role,&#x000a0;B cell hyperreactivity with immunoglobulin production is also implicated. Active sarcoidosis has also been associated with plasmatic hypergammaglobulinemia. Angiotensin-converting enzyme (ACE) levels correlated with elevated soluble HLA class I antigens levels in serum.<xref ref-type="bibr" rid="article-28721.r8">[8]</xref></p>
      </sec>
      <sec id="article-28721.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Biopsy of lymph nodes will reveal non-caseating granulomas.</p>
      </sec>
      <sec id="article-28721.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Symptoms are variable; typically, patients present with&#x000a0;a persistent dry cough,&#x000a0;fatigue, and shortness of breath. Other symptoms include painful red lumps on the skin, uveitis with the blurring of vision, hoarseness of voice, palpable lymph nodes at multiple sites including the axilla&#x000a0;and neck, painful swollen joints, hearing loss, seizures, or psychiatric disorders could be observed as part of neurological manifestations. Cardiomyopathy, conduction defects, renal calculi, and enlarged liver are observed in a few cases.</p>
        <p>A wide range of cutaneous manifestations can be classified as papular, maculopapular, nodular, subcutaneous, hypopigmented, and plaque sarcoidosis. The most common lesions in cutaneous sarcoidosis are papular sarcoidosis involving the upper half of the face, the back of the neck, and&#x000a0;previous trauma, scar sites, and tattoos. Lupus pernio is a variant of cutaneous sarcoidosis that presents with violaceous or erythematous papules, plaques, or nodules, mainly involving the central facial skin. Other well-described skin manifestations of sarcoidosis include nodular sarcoidosis. Plaque-like lesions and subcutaneous non-tender nodules are also commonly seen.</p>
        <p>Erythema nodosum (EN) is seen in a variety of other conditions, including sarcoidosis, and usually presents with painful nodules on shins. It is characterized as panniculitis and is a part of L&#x000f6;fgren syndrome. Skin lesions can appear up to 10 or more years after the initial injury or tattoo.</p>
        <p>Ocular manifestations are seen in close to 50% of patients, of which the most common clinical feature is uveitis. The CD4/CD8 ratio of vitreous lymphocytes has prognostic value.</p>
        <p>Heart block and sudden death have also been reported in sarcoidosis. Prophylactic insertion of an implantable cardioverter-defibrillator (ICD) is recommended in patients who develop cardiac sarcoidosis.</p>
        <p>CNS manifestations include diabetes insipidus followed by hyperprolactinemia.</p>
        <p>The quality of life of symptomatic patients is poor. Many develop psychiatric symptoms, including depression and anxiety.</p>
      </sec>
      <sec id="article-28721.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>
<bold>Lab Tests</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Complete blood count and differential looking for anemia, leukopenia, thrombocytopenia, liver function tests, blood urea nitrogen, creatinine, glucose, electrolytes, and serum calcium looking for hypercalcemia. ESR and C-reactive protein are nonspecific tests, often elevated.</p>
          </list-item>
          <list-item>
            <p>Elevated serum alkaline phosphatase concentration suggests diffuse granulomatous hepatic involvement.</p>
          </list-item>
          <list-item>
            <p>Serologic tests can be considered, including serum&#x000a0;angiotensin-converting&#x000a0;enzyme (ACE), adenosine deaminase, serum amyloid A, and soluble interleukin-2 receptor.</p>
          </list-item>
          <list-item>
            <p>Kveim test is similar to tuberculin skin test and evokes a sarcoid granulomatous response. It is of limited significance.</p>
          </list-item>
        </list>
        <p>
<bold>Radiographic Tests</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Lungs are the main site of involvement; imaging tests include chest radiograph, CT of the chest, fluorine-18-fluorodeoxyglucose-positron emission tomography (FDG-PET), gallium-67,&#x000a0;thallium-201, technetium sestamibi (MIBI-Tc), and single-photon emission computed tomography (SPECT).</p>
          </list-item>
          <list-item>
            <p>Cardiac or CNS-affected sarcoidosis is better diagnosed with the help of an MRI or PET scan.</p>
          </list-item>
          <list-item>
            <p>Pulmonary function tests may reveal a decrease in DLCO, and a restrictive pattern is seen in advanced cases. About 10% of patients will have an obstructive pattern. Patients with DLCO less than 60% predicted, combined with oxygen saturation of less than 90 on the walk test, need to be evaluated for pulmonary hypertension.</p>
          </list-item>
        </list>
        <p>
<bold>Radiographic Stages</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Stage I: Presence of bilateral hilar adenopathy</p>
          </list-item>
          <list-item>
            <p>Stage II: Bilateral hilar adenopathy and reticular opacities</p>
          </list-item>
          <list-item>
            <p>Stage III: Reticular opacities with shrinking hilar nodes (mainly infiltrates)</p>
          </list-item>
          <list-item>
            <p>Stage IV: Reticular opacities with fibrosis</p>
          </list-item>
        </list>
        <p>In the case of a clear chest X-ray in a patient with unexplained dyspnea or cough, (HRCT) of the chest should be considered.</p>
        <p>
<bold>Histopathology</bold>
</p>
        <p>Sarcoidosis characteristically has noncaseating granulomas with aggregates of epithelioid histiocytes, giant cells, and mature macrophages.</p>
        <p>To rule out systemic disease, pulmonary function testing, electrocardiogram, echocardiography, urinalysis, and tuberculin skin testing should be considered.</p>
        <p>Follow-up of the pulmonary disease can be done with pulmonary function tests and a carbon monoxide diffusion capacity test of the lungs for carbon monoxide (DLCO).<xref ref-type="bibr" rid="article-28721.r9">[9]</xref><xref ref-type="bibr" rid="article-28721.r10">[10]</xref><xref ref-type="bibr" rid="article-28721.r11">[11]</xref></p>
        <p>A biopsy is often required to confirm the diagnosis. Transbronchial biopsy has a high yield. If that fails, then a mediastinoscopy to perform a lymph node biopsy is required. The key feature is noncaseating granulomas in the absence of mycobacteria and fungi.</p>
      </sec>
      <sec id="article-28721.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Pulmonary sarcoidosis is often an asymptomatic, non-progressive disease and requires no treatment, as a majority of patients undergo spontaneous remission. Close&#x000a0;monitoring of symptoms, chest radiograph, and pulmonary function is continued at three to six-month intervals should be considered in asymptomatic patients. For patients with pulmonary sarcoidosis causing worsening symptoms, stage II to III radiographic findings should be considered for oral glucocorticoids at&#x000a0;0.3 to 0.6&#x000a0;mg/kg for 4 to 6 weeks. If there is no improvement in symptoms, radiographic abnormalities, and pulmonary function tests, steroids may be continued for an additional four to six weeks. Maintainance steroids are not needed; steroid tapering to a dose of 0.25 to 0.5 mg/kg&#x000a0;(usually 10 to 20 mg) per day should be considered over at least six to eight months. Methotrexate,&#x000a0;azathioprine, infliximab, leflunomide, and antimalarial agents may be considered as&#x000a0;steroid-sparing agents in patients who are&#x000a0;unable to tolerate steroids.<xref ref-type="bibr" rid="article-28721.r12">[12]</xref><xref ref-type="bibr" rid="article-28721.r13">[13]</xref></p>
        <p>Lung transplant is an option for patients with end-stage lung disease. However, the transplant is also associated with risks and the need to take immunosuppressive therapy for life.</p>
      </sec>
      <sec id="article-28721.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <list list-type="bullet">
          <list-item>
            <p>Tuberculosis</p>
          </list-item>
          <list-item>
            <p>Cat scratch disease</p>
          </list-item>
          <list-item>
            <p>Lung cancer</p>
          </list-item>
          <list-item>
            <p>Lymphoma</p>
          </list-item>
          <list-item>
            <p>Occupational lung disease</p>
          </list-item>
          <list-item>
            <p>Fungal infection</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-28721.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Asymptomatic patients do not require treatment and often remain stable for many years. However, those who develop symptomatic lung or extrapulmonary disease tend to have a guarded prognosis. Relapse of symptoms is common, and many patients with advanced disease develop dyspnea and pulmonary hypertension. The overall mortality rate for untreated patients is about 5%. However, prolonged treatment with corticosteroids is not benign, and the adverse effects of these drugs are common.</p>
      </sec>
      <sec id="article-28721.s12" sec-type="Complications">
        <title>Complications</title>
        <list list-type="bullet">
          <list-item>
            <p>Pulmonary hypertension</p>
          </list-item>
          <list-item>
            <p>End-stage lung disease</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-28721.s13" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Sarcoidosis has no obvious cause, and hence prevention is not possible. The disorder also resolves spontaneously; hence, treatment is not always required. However, severe cases do&#x000a0;need follow-up. The management of patients with sarcoidosis is best done in an interprofessional fashion with a team of healthcare workers that includes a cardiologist, neurologist, radiologist, pulmonologist, cardiac nurse, respiratory therapist, and pharmacist. The patient needs regular chest X-rays since it is a marker for disease progression. Some patients may benefit from pulmonary rehabilitation and the use of bronchodilators. If the disease is advanced, a regular eye exam is important.</p>
        <p>Symptomatic patients need drug therapy, and the pharmacist needs to emphasize the importance of compliance and the need to follow up since most drugs have adverse side effects. Patients who fail to respond to steroids may need potent biological agents. In addition, patients with end-stage lung disease may need to be seen by a transplant nurse to determine their eligibility. Further, patients with eye symptoms should be referred to an ophthalmologist.</p>
        <p>At each clinic visit, the nurse should ensure that the patient gets a regular 12-lead ECG because the heart block is not uncommon. The pharmacist and nurse should educate the patient on the importance of&#x000a0;discontinuing smoking and abstaining from alcohol. Finally, patients who are managed with steroids should be educated by all members of the team about the side effects of the drugs used. Only through such an interprofessional team approach can the outcomes of sarcoidosis be improved.<xref ref-type="bibr" rid="article-28721.r14">[14]</xref><xref ref-type="bibr" rid="article-28721.r15">[15]</xref> [Level 5]</p>
        <p>
<bold>Outcomes</bold>
</p>
        <p>In many patients with sarcoidosis, no&#x000a0;treatment is required, and the disorder spontaneously resolves. However, the disease may take a fulminant course with severe symptoms in a certain number of people. Factors that indicate a poor prognosis include significant chest imaging findings, extrapulmonary involvement, and the presence of pulmonary hypertension. Many studies indicate that a chest X-ray is an excellent marker for disease prognosis. In severe cases, patients may require oxygen and experience heart block and respiratory failure. Data regarding mortality are not available because, in many cases, long-term follow-up is missing. Overall, it appears that&#x000a0;about one-fifth of patients develop functional impairment, and there is a mortality rate of 3% to 5% in patients who are not treated. The highest mortality rates are in African American females past the fifth decade of life.<xref ref-type="bibr" rid="article-28721.r16">[16]</xref><xref ref-type="bibr" rid="article-28721.r17">[17]</xref>&#x000a0;[Level 5]</p>
      </sec>
      <sec id="article-28721.s14">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=28721&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=28721">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/lung-disease-respiratory-health/sarcoidosis/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=28721">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/28721/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=28721">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-28721.s15">
        <fig id="article-28721.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Bilateral Hilar Adenopathy Contributed by S Dulebohn, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="sarcoidosis" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-28721.s16">
        <title>References</title>
        <ref id="article-28721.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ma</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Gal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Koss</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Reprint of: The pathology of pulmonary sarcoidosis: update.</article-title>
            <source>Semin Diagn Pathol</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>35</volume>
            <issue>5</issue>
            <fpage>324</fpage>
            <page-range>324-333</page-range>
            <pub-id pub-id-type="pmid">30262157</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28721.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Landi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Carleo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cillis</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Rottoli</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Sarcoidosis: proteomics and new perspectives for improving personalized medicine.</article-title>
            <source>Expert Rev Proteomics</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>15</volume>
            <issue>10</issue>
            <fpage>829</fpage>
            <page-range>829-835</page-range>
            <pub-id pub-id-type="pmid">30251559</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28721.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Petek</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Rosenthal</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Patton</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Behnia</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Keller</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Collins</surname>
                <given-names>BF</given-names>
              </name>
              <name>
                <surname>Cheng</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Ho</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Bravo</surname>
                <given-names>PE</given-names>
              </name>
              <name>
                <surname>Mikacenic</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Raghu</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Cardiac sarcoidosis: Diagnosis confirmation by bronchoalveolar lavage and lung biopsy.</article-title>
            <source>Respir Med</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>144S</volume>
            <fpage>S13</fpage>
            <page-range>S13-S19</page-range>
            <pub-id pub-id-type="pmid">30249376</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28721.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>M&#x000f8;ller</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hellmund</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Hilberg</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>L&#x000f8;kke</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>[Sarcoidosis].</article-title>
            <source>Ugeskr Laeger</source>
            <year>2018</year>
            <month>Aug</month>
            <day>20</day>
            <volume>180</volume>
            <issue>34</issue>
            <pub-id pub-id-type="pmid">30152318</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28721.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sohn</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>HK</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>YJ</given-names>
              </name>
            </person-group>
            <article-title>Viewpoints in the diagnosis and treatment of cardiac sarcoidosis: Proposed modification of current guidelines.</article-title>
            <source>Clin Cardiol</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>41</volume>
            <issue>10</issue>
            <fpage>1386</fpage>
            <page-range>1386-1394</page-range>
            <pub-id pub-id-type="pmid">30144116</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28721.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wills</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Adjemian</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Fontana</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Steiner</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Daniel-Wayman</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Olivier</surname>
                <given-names>KN</given-names>
              </name>
              <name>
                <surname>Prevots</surname>
                <given-names>DR</given-names>
              </name>
            </person-group>
            <article-title>Sarcoidosis-associated Hospitalizations in the United States, 2002 to 2012.</article-title>
            <source>Ann Am Thorac Soc</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>15</volume>
            <issue>12</issue>
            <fpage>1490</fpage>
            <page-range>1490-1493</page-range>
            <pub-id pub-id-type="pmid">30199648</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28721.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yoon</surname>
                <given-names>HY</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>YJ</given-names>
              </name>
              <name>
                <surname>Song</surname>
                <given-names>JW</given-names>
              </name>
            </person-group>
            <article-title>Prevalence and incidence of sarcoidosis in Korea: a nationwide population-based study.</article-title>
            <source>Respir Res</source>
            <year>2018</year>
            <month>Aug</month>
            <day>28</day>
            <volume>19</volume>
            <issue>1</issue>
            <fpage>158</fpage>
            <pub-id pub-id-type="pmid">30153830</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28721.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Celada</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Kropski</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Herazo-Maya</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Luo</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Creecy</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Abad</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Chioma</surname>
                <given-names>OS</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Hassell</surname>
                <given-names>NE</given-names>
              </name>
              <name>
                <surname>Shaginurova</surname>
                <given-names>GI</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Kerrigan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mason</surname>
                <given-names>WR</given-names>
              </name>
              <name>
                <surname>Baughman</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Ayers</surname>
                <given-names>GD</given-names>
              </name>
              <name>
                <surname>Bernard</surname>
                <given-names>GR</given-names>
              </name>
              <name>
                <surname>Culver</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Montgomery</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Maher</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Molyneaux</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>Noth</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Mutsaers</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Prele</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Peebles</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Newcomb</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Kaminski</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Blackwell</surname>
                <given-names>TS</given-names>
              </name>
              <name>
                <surname>Van Kaer</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Drake</surname>
                <given-names>WP</given-names>
              </name>
            </person-group>
            <article-title>PD-1 up-regulation on CD4<sup>+</sup> T cells promotes pulmonary fibrosis through STAT3-mediated IL-17A and TGF-&#x003b2;1 production.</article-title>
            <source>Sci Transl Med</source>
            <year>2018</year>
            <month>Sep</month>
            <day>26</day>
            <volume>10</volume>
            <issue>460</issue>
            <pub-id pub-id-type="pmid">30257954</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28721.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shimada</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Furusawa</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ishikawa</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kamakura</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Suzuki</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Watanabe</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Fujiwara</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Tominaga</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Komatsuzaki</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Natsume</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Development of mediastinal adenitis six weeks after endobronchial ultrasound-guided transbronchial needle aspiration.</article-title>
            <source>Respir Med Case Rep</source>
            <year>2018</year>
            <volume>25</volume>
            <fpage>161</fpage>
            <page-range>161-164</page-range>
            <pub-id pub-id-type="pmid">30175038</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28721.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kobak</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yildiz</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Semiz</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Orman</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Elderly-onset sarcoidosis: A single center comparative study.</article-title>
            <source>Reumatol Clin (Engl Ed)</source>
            <year>2020</year>
            <season>May-Jun</season>
            <volume>16</volume>
            <issue>3</issue>
            <fpage>235</fpage>
            <page-range>235-238</page-range>
            <pub-id pub-id-type="pmid">30054252</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28721.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Niederer</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Al-Janabi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lightman</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Tomkins-Netzer</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Serum Angiotensin-Converting Enzyme Has a High Negative Predictive Value in the Investigation for Systemic Sarcoidosis.</article-title>
            <source>Am J Ophthalmol</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>194</volume>
            <fpage>82</fpage>
            <page-range>82-87</page-range>
            <pub-id pub-id-type="pmid">30053466</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28721.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>P&#x00142;usa</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>[Advances in differential diagnosis and treatment of patients with sarcoidosis].</article-title>
            <source>Pol Merkur Lekarski</source>
            <year>2018</year>
            <month>Mar</month>
            <day>27</day>
            <volume>44</volume>
            <issue>261</issue>
            <fpage>135</fpage>
            <page-range>135-138</page-range>
            <pub-id pub-id-type="pmid">29601563</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28721.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>West</surname>
                <given-names>SG</given-names>
              </name>
            </person-group>
            <article-title>Current management of sarcoidosis I: pulmonary, cardiac, and neurologic manifestations.</article-title>
            <source>Curr Opin Rheumatol</source>
            <year>2018</year>
            <month>May</month>
            <volume>30</volume>
            <issue>3</issue>
            <fpage>243</fpage>
            <page-range>243-248</page-range>
            <pub-id pub-id-type="pmid">29389828</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28721.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dubaniewicz</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>[The diagnostic algorithm of practice in pulmonary and extrapulmonary sarcoidosis].</article-title>
            <source>Pol Merkur Lekarski</source>
            <year>2018</year>
            <month>Mar</month>
            <day>27</day>
            <volume>44</volume>
            <issue>261</issue>
            <fpage>101</fpage>
            <page-range>101-109</page-range>
            <pub-id pub-id-type="pmid">29601557</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28721.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Matsou</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tsaousis</surname>
                <given-names>KT</given-names>
              </name>
            </person-group>
            <article-title>Management of chronic ocular sarcoidosis: challenges and solutions.</article-title>
            <source>Clin Ophthalmol</source>
            <year>2018</year>
            <volume>12</volume>
            <fpage>519</fpage>
            <page-range>519-532</page-range>
            <pub-id pub-id-type="pmid">29593377</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28721.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Salama</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Abdullah</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wahab</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Eigbire</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Hoefen</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Alweis</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Cardiac sarcoidosis and ventricular arrhythmias. A rare association of a rare disease. A retrospective cohort study from the National Inpatient Sample and current evidence for management.</article-title>
            <source>Cardiol J</source>
            <year>2020</year>
            <volume>27</volume>
            <issue>3</issue>
            <fpage>272</fpage>
            <page-range>272-277</page-range>
            <pub-id pub-id-type="pmid">30234899</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28721.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jachiet</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Lhote</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Rufat</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Pha</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Haroche</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Crozier</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Dupel-Potier</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Psimaras</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Amoura</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Cohen Aubart</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Clinical, imaging, and histological presentations and outcomes of stroke related to sarcoidosis.</article-title>
            <source>J Neurol</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>265</volume>
            <issue>10</issue>
            <fpage>2333</fpage>
            <page-range>2333-2341</page-range>
            <pub-id pub-id-type="pmid">30109479</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
